
uniQure N.V. QURE
$ 25.93
1.09%
Quarterly report 2025-Q3
added 11-10-2025
Country |
|
IPO year |
2014 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
48.6 M |
Market Cap[1] |
$ 1.26 B |
EBITDA (LTM) |
$ -211 M |
P/E (LTM) |
-6.78 |
P/S (LTM) |
97.74 |
EPS (LTM) |
-3.8 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Aptorum Group Limited
APM
|
$ 0.83 | 2.17 % | $ 4.53 M | Nasdaq Global Select Market | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
BioCryst Pharmaceuticals
BCRX
|
$ 6.26 | -1.88 % | $ 1.29 B | Nasdaq Global Select Market | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
Biogen
BIIB
|
$ 192.06 | -4.53 % | $ 28.1 B | Nasdaq Global Select Market,SPB | ||
|
Bristol-Myers Squibb Company
BMY
|
$ 60.58 | -2.25 % | $ 123 B | NYSE,SPB | ||
|
BioNTech SE
BNTX
|
$ 110.14 | 3.3 % | $ 27.2 B | Nasdaq Global Select Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Adagene
ADAG
|
$ 2.6 | -1.12 % | $ 146 M | Nasdaq Global Market | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
BioXcel Therapeutics
BTAI
|
$ 1.58 | 5.53 % | $ 4.01 M | Nasdaq Global Select Market,SPB | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
BeyondSpring
BYSI
|
$ 1.51 | 0.33 % | $ 60.9 M | Nasdaq Capital Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Alterity Therapeutics Limited
ATHE
|
$ 3.51 | -0.52 % | $ 8.45 B | Nasdaq Capital Market | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 4.21 | 1.2 % | $ 9.16 B | NYSE American | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
Capricor Therapeutics
CAPR
|
$ 25.04 | 1.29 % | $ 671 M | Nasdaq Capital Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
CASI Pharmaceuticals
CASI
|
$ 0.93 | 0.47 % | $ 127 M | Nasdaq Capital Market | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | ||
|
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
Akebia Therapeutics
AKBA
|
$ 1.49 | 7.19 % | $ 279 M | Nasdaq Global Market | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | ||
|
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | ||
|
Ascendis Pharma A/S
ASND
|
$ 221.8 | -0.16 % | $ 5 B | Nasdaq Global Select Market | ||
|
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | ||
|
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | ||
|
Celldex Therapeutics
CLDX
|
$ 24.69 | 3.91 % | $ 1.59 M | Nasdaq Global Select Market | ||
|
Cellectis S.A.
CLLS
|
$ 3.72 | 4.2 % | $ 116 M | Nasdaq Global Market | ||
|
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | ||
|
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | Nasdaq Capital Market | ||
|
Burford Capital Limited
BUR
|
$ 8.96 | 0.45 % | $ 1.41 B | NYSE | ||
|
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | ||
|
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | ||
|
Aytu BioScience
AYTU
|
$ 2.35 | -1.81 % | $ 14.8 M | Nasdaq Capital Market | ||
|
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.